Pediatric Calfactant in Acute Respiratory Distress Syndrome Trial*
Authors:
- Douglas F. WillsonDWDouglas F. Willson
- Neal J. ThomasNTNeal J. Thomas
- Robert TamburroRTRobert Tamburro
- Edward TruemperETEdward Truemper
- Jonathon TruwitJTJonathon Truwit
- Mark ConawayMCMark Conaway
- Christine TraulCTChristine Traul
- Edmund E. EganEEEdmund E. Egan
- 1 September 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 14 (7) , 657-665
Abstract
Our previous studies in children with acute lung injury/acute respiratory distress syndrome demonstrated improved outcomes with exogenous surfactant (calfactant) administration. Sample sizes in those studies were small, however, and the subject populations heterogeneous, thus making recommendations tenuous. To investigate the efficacy of surfactant administration in a larger, more homogenous population of children with lung injury/acute respiratory distress syndrome due to direct lung injury. Masked, randomized, placebo-controlled trial in 24 children's hospitals in six different countries. Children 37 weeks postconception to 18 years old with lung injury/acute respiratory distress syndrome due to direct lung injury were randomized to receive up to three doses of 30 mg/cm height of surfactant (calfactant) versus placebo (air) within 48 hours of intubation and initiation of mechanical ventilation. The primary outcome was mortality at 90 days. Ventilator-free days, changes in oxygenation, and adverse events were also assessed. The study was stopped at the sponsor's request after the second interim analysis for presumed futility. A total of 110 subjects were enrolled, with consent withdrawn from one whose data are unavailable. There were no significant differences between groups except in hospital-free days (10.4 ± 7.8 placebo vs 6.4 ± 7.8 surfactant; p = 0.01). Overall 90-day mortality was 11% (seven surfactant, five placebo). No immediate improvement in oxygenation was associated with surfactant administration. Surfactant did not improve outcomes relative to placebo in this trial of children with direct lung injury/acute respiratory distress syndrome. Differences in concentration of the surfactant, failure to recruit the lung during surfactant administration, or using two rather than four position changes during administration are possible explanations for the difference from previous studies. Exogenous surfactant cannot be recommended at this time for children with direct lung injury/acute respiratory distress syndrome.Keywords
This publication has 24 references indexed in Scilit:
- Effect of Exogenous Surfactant (Calfactant) in Pediatric Acute Lung InjuryA Randomized Controlled TrialJAMA, 2005
- Pulmonary Inflammation Disrupts Surfactant Function duringPneumocystis cariniiPneumoniaInfection and Immunity, 2001
- Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000
- Multiple Mechanisms of Lung Surfactant InhibitionPediatric Research, 1999
- Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failureCritical Care Medicine, 1999
- Calf's lung surfactant extract in acute hypoxemic respiratory failure in childrenCritical Care Medicine, 1996
- Surfactant Alterations in Severe Pneumonia, Acute Respiratory Distress Syndrome, and Cardiogenic Lung EdemaAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Pulmonary Surfactant TherapyNew England Journal of Medicine, 1993
- Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome.Journal of Clinical Investigation, 1991
- Surfactant Abnormalities in Patients with Respiratory Failure after Multiple TraumaAmerican Review of Respiratory Disease, 1989